Please login to the form below

Not currently logged in
Email:
Password:

Mundipharma appoints Dr Alberto Martinez as president and CEO

He succeeds Antony Mattessich, who leaves after 12 years with the networked company

Alberto MartinezMundipharma has appointed Dr Alberto Martinez as its new president and chief executive officer, succeeding Antony Mattessich, who leaves the network after 12 years of service to pursue his career in the US.

Dr Martinez’ career has seen him gain expertise in the healthcare and pharmaceutical fields, more specifically in the strategic, financial and operational capacity.

His new role will see him take responsibility for strengthening Mundipharma’s network in Europe and focus on its alliances.

Additionally, research and development, global manufacturing, supply chain and IT functions will fall under Dr Martinez’s new remit.

He said: “I feel honoured and privileged to be given the opportunity to lead the Mundipharma organisations in Europe in the next chapter of our evolution and success. I am committed to ensure that we remain ambitious and agile so we continue to bring valuable and innovative medicines to patients and healthcare providers as a successful, diversified and forward-thinking organisation.”

Dr Martinez originally joined the Mundipharma network in 2003 and has held roles of increasing responsibility over the past 14 years.

Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.

8th January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....